Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Inherit Metab Dis ; 43(6): 1370-1381, 2020 11.
Article in English | MEDLINE | ID: mdl-32852845

ABSTRACT

Congenital disorders of glycosylation (CDG) are a growing group of inborn metabolic disorders with multiorgan presentation. SLC39A8-CDG is a severe subtype caused by biallelic mutations in the manganese transporter SLC39A8, reducing levels of this essential cofactor for many enzymes including glycosyltransferases. The current diagnostic standard for disorders of N-glycosylation is the analysis of serum transferrin. Exome and Sanger sequencing were performed in two patients with severe neurodevelopmental phenotypes suggestive of CDG. Transferrin glycosylation was analyzed by high-performance liquid chromatography (HPLC) and isoelectric focusing in addition to comprehensive N-glycome analysis using matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry (MS). Atomic absorption spectroscopy was used to quantify whole blood manganese levels. Both patients presented with a severe, multisystem disorder, and a complex neurological phenotype. Magnetic resonance imaging (MRI) revealed a Leigh-like syndrome with bilateral T2 hyperintensities of the basal ganglia. In patient 1, exome sequencing identified the previously undescribed homozygous variant c.608T>C [p.F203S] in SLC39A8. Patient 2 was found to be homozygous for c.112G>C [p.G38R]. Both individuals showed a reduction of whole blood manganese, though transferrin glycosylation was normal. N-glycome using MALDI-TOF MS identified an increase of the asialo-agalactosylated precursor N-glycan A2G1S1 and a decrease in bisected structures. In addition, analysis of heterozygous CDG-allele carriers identified similar but less severe glycosylation changes. Despite its reliance as a clinical gold standard, analysis of transferrin glycosylation cannot be categorically used to rule out SLC39A8-CDG. These results emphasize that SLC39A8-CDG presents as a spectrum of dysregulated glycosylation, and MS is an important tool for identifying deficiencies not detected by conventional methods.


Subject(s)
Basal Ganglia/physiopathology , Cation Transport Proteins/genetics , Congenital Disorders of Glycosylation/genetics , Congenital Disorders of Glycosylation/physiopathology , Adolescent , Cation Transport Proteins/deficiency , Child , Child, Preschool , Chromatography, High Pressure Liquid , Female , Glycosylation , Humans , Infant , Magnetic Resonance Imaging , Male , Manganese/metabolism , Mass Spectrometry , Phenotype , Transferrin/analysis , Exome Sequencing , Young Adult
2.
J Inherit Metab Dis ; 43(5): 1024-1036, 2020 09.
Article in English | MEDLINE | ID: mdl-32160317

ABSTRACT

Hydrogen sulfide, a signaling molecule formed mainly from cysteine, is catabolized by sulfide:quinone oxidoreductase (gene SQOR). Toxic hydrogen sulfide exposure inhibits complex IV. We describe children of two families with pathogenic variants in SQOR. Exome sequencing identified variants; SQOR enzyme activity was measured spectrophotometrically, protein levels evaluated by western blotting, and mitochondrial function was assayed. In family A, following a brief illness, a 4-year-old girl presented comatose with lactic acidosis and multiorgan failure. After stabilization, she remained comatose, hypotonic, had neurostorming episodes, elevated lactate, and Leigh-like lesions on brain imaging. She died shortly after. Her 8-year-old sister presented with a rapidly fatal episode of coma with lactic acidosis, and lesions in the basal ganglia and left cortex. Muscle and liver tissue had isolated decreased complex IV activity, but normal complex IV protein levels and complex formation. Both patients were homozygous for c.637G > A, which we identified as a founder mutation in the Lehrerleut Hutterite with a carrier frequency of 1 in 13. The resulting p.Glu213Lys change disrupts hydrogen bonding with neighboring residues, resulting in severely reduced SQOR protein and enzyme activity, whereas sulfide generating enzyme levels were unchanged. In family B, a boy had episodes of encephalopathy and basal ganglia lesions. He was homozygous for c.446delT and had severely reduced fibroblast SQOR enzyme activity and protein levels. SQOR dysfunction can result in hydrogen sulfide accumulation, which, consistent with its known toxicity, inhibits complex IV resulting in energy failure. In conclusion, SQOR deficiency represents a new, potentially treatable, cause of Leigh disease.


Subject(s)
Hydrogen Sulfide/metabolism , Leigh Disease/enzymology , Mitochondria/metabolism , Oxidoreductases Acting on Sulfur Group Donors/genetics , Quinone Reductases/physiology , Acidosis, Lactic/pathology , Brain Diseases/pathology , Child, Preschool , Electron Transport Complex IV/metabolism , Family , Female , Homozygote , Humans , Hydrogen Sulfide/chemistry , Kinetics , Leigh Disease/metabolism , Magnetic Resonance Imaging , Male , Oxidation-Reduction , Quinone Reductases/chemistry
3.
J Assist Reprod Genet ; 35(6): 985-992, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29936652

ABSTRACT

OBJECTIVES: In vitro fertilization (IVF) has been linked to an increased risk for imprinting disorders in offspring. The data so far have predominantly been retrospective, comparing the rate of IVF conceptions in affected patients with controls. We describe a series of fetuses with omphalocele that were tested for Beckwith-Wiedemann syndrome (BWS) and subsequently ascertained as to whether pregnancies were conceived by assisted reproductive technologies (ART). METHODS: Fetuses were tested for BWS by Southern blot, PCR based methods, and methylation analysis to identify the imprinting status at primarily the IC2 locus, KCNQ1OT1, as well as IC1, H19/IGF-2. Some fetuses were also tested for uniparental disomy of chromosome 11p. RESULTS: We tested 301 fetuses with omphalocele for BWS. Forty samples were positive. Sixteen were from IVF pregnancies, for an overall rate of 40%. Such as high proportion of IVF pregnancies in a series of BWS-positive fetuses has not been described previously. Possible factors such as twinning and ascertainment bias are discussed. CONCLUSION: We found about a 20-fold overrepresentation of IVF cases in fetuses with BWS/omphalocele when compared with the rate of ART pregnancies in the USA (p < .0001). Our series provides support for an association of IVF and BWS. Patients should be counseled about these risks and made aware of the availability of prenatal diagnosis for detection.


Subject(s)
Beckwith-Wiedemann Syndrome/genetics , Genomic Imprinting/genetics , Prenatal Diagnosis , Reproductive Techniques, Assisted/adverse effects , Beckwith-Wiedemann Syndrome/epidemiology , Beckwith-Wiedemann Syndrome/physiopathology , DNA Methylation/genetics , Female , Fertilization in Vitro , Fetus/physiopathology , Humans , Male , Pregnancy
4.
Pediatr Dev Pathol ; 11(5): 377-83, 2008.
Article in English | MEDLINE | ID: mdl-18260692

ABSTRACT

Androgenetic/biparental mosaicism, in which a subset of cells has complete paternal uniparental disomy, is associated with placental mesenchymal dysplasia (PMD), which is compatible with fetal development, indicating that fetal organs could also have androgenetic/biparental mosaicism, but few cases of somatic mosaicism have been described. A hepatic mesenchymal hamartoma (HMH) was resected from an otherwise healthy, nondysmorphic, 11-month-old girl, whose prenatal development was complicated by PMD. Placenta, HMH, histologically normal liver, and other tissues were examined for androgenetic/biparental mosaicism by analysis of (1) polymorphic DNA microsatellite markers, (2) the methylation status of an imprinted gene, SNRPN, and (3) immunohistochemically detectable protein products of the imprinted genes p57KIP2 and PHLDA2. The patient's liver, HMH, and 1 placental sample demonstrated an increased ratio of paternal to maternal alleles, indicating androgenetic/biparental mosaicism. The androgenetic component comprised 26% to 60% of the cells. Other tissues, including a 2nd placental sample, white blood cells, umbilical cord, and abdominal fascia, had no detectable androgenetic component. Methylation analysis confirmed a relative excess of the paternally imprinted SNRPN homolog in the normal liver, HMH, and placenta. Placental p57KIP2 immunoreactivity was consistent with androgenetic/biparental mosaicism, but neither p57KIP2 nor PHLDA2 immunohistochemistry were informative for HMH, because neither antigen was detected in control liver samples. We report androgenetic/biparental mosaicism in nonplacental tissues of an infant with PMD and provide the 1st description of genome-wide paternal uniparental disomy in HMH. Androgenetic/biparental mosaicism appears to play a role in the pathogenesis of HMH and other somatic lesions, particularly those associated with PMD.


Subject(s)
Hamartoma/pathology , Liver Diseases/pathology , Mosaicism , Placenta Diseases/pathology , Uniparental Disomy/pathology , Cesarean Section , Female , Follow-Up Studies , Hamartoma/diagnostic imaging , Hamartoma/genetics , Humans , Immunohistochemistry , Infant, Newborn , Liver Diseases/diagnostic imaging , Liver Diseases/genetics , Liver Diseases/surgery , Placenta Diseases/diagnostic imaging , Placenta Diseases/genetics , Pregnancy , Pregnancy Trimester, Third , Time Factors , Treatment Outcome , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL
...